Research advances in photoactivatable CRISPR gene editing technology.
10.3760/cma.j.cn511374-20211027-00851
- Author:
Jie ZHAO
1
;
Shuming CAO
;
Yang ZHANG
;
Yue GUO
;
Bing LI
;
Jianxiong MA
;
Xinlong MA
Author Information
1. Tianjin Hospital, Tianjin University, Tianjin 300211, China. maxinlong8686@yeah.net.
- Publication Type:Journal Article
- MeSH:
CRISPR-Cas Systems;
DNA;
Gene Editing;
Humans;
Technology
- From:
Chinese Journal of Medical Genetics
2022;39(9):1025-1029
- CountryChina
- Language:Chinese
-
Abstract:
Since the emergence of CRISPR/Cas9, gene editing technologies have attracted increasing attention, in particular type II systems, in which nucleases consist of only a single protein. The effectors include type II Cas9, type V Cas12 and type VI Cas13, which allow precise genomic DNA or RNA editing. Catalytically inactive CRISPR/Cas9 can also be used as a platform to recruit effectors such as transcription factors, epigenetic factors, and/or base modification enzymes to target gene loci. On the other hand, optogenetics offers spatial, temporal, and reversible control of biological processes. CRISPR and optogenetics can enable precise gene editing in vitro and in vivo at the spatiotemporal level, which has a broad applicability in biology and medicine. This article has provided a review for the research advance in photoactivatable CRISPR systems, with details for the design and application of such tools and a discussion over the limitations of the current methods, which may shed light on this emerging field.
